Literature DB >> 26126195

Novel preservation methods to increase the quality of older kidneys.

Aukje Brat1, Robert A Pol, Henri G D Leuvenink.   

Abstract

PURPOSE OF REVIEW: The purpose of this review was to summarize the novel developments in preservation of older kidneys. RECENT
FINDINGS: The importance of older donors as a source of renal grafts is increasing, with a concomitant increase of posttransplant failure. Preservation of kidneys retrieved from older donors through hypothermic machine perfusion reduces delayed graft function rate and increases long-term graft survival. Assessment of renal function and selection through biomarkers or perfusion criteria to predict posttransplant function are limited. Normothermic perfusion offers the benefit of reperfusion under ideal circumstances, thereby reducing ischemic injury while having the opportunity to test graft viability and preselect kidneys on graft-specific characteristics. Both preservation methods enable active treatment of the isolated graft prior to transplantation, with stem cells or pharmaceuticals.
SUMMARY: Older kidneys are more prone to acute kidney injury during ischemic periods combined with an impaired ability to fully recover after transplantation. Novel preservation and resuscitation methods provide the opportunity to select transplantable kidneys better founded or even repair re-existing damage reducing the risk of impaired graft function and improving survival.

Entities:  

Mesh:

Year:  2015        PMID: 26126195     DOI: 10.1097/MOT.0000000000000215

Source DB:  PubMed          Journal:  Curr Opin Organ Transplant        ISSN: 1087-2418            Impact factor:   2.640


  7 in total

1.  Intra-Organ Delivery of Nanotherapeutics for Organ Transplantation.

Authors:  Bilal Hussain; Vivek Kasinath; Joren C Madsen; Jonathan Bromberg; Stefan G Tullius; Reza Abdi
Journal:  ACS Nano       Date:  2021-10-29       Impact factor: 18.027

2.  Nanotechnological Approaches to Immunosuppression and Tolerance Induction.

Authors:  Kunal Patel; Carl Atkinson; Danh Tran; Satish N Nadig
Journal:  Curr Transplant Rep       Date:  2017-04-17

3.  Strategies to Restore Adenosine Triphosphate (ATP) Level After More than 20 Hours of Cold Ischemia Time in Human Marginal Kidney Grafts.

Authors:  Matteo Ravaioli; Maurizio Baldassare; Francesco Vasuri; Gianandrea Pasquinelli; Maristella Laggetta; Sabrina Valente; Vanessa De Pace; Flavia Neri; Antonio Siniscalchi; Chiara Zanfi; Valentina R Bertuzzo; Paolo Caraceni; Davide Trerè; Pasquale Longobardi; Antonio D Pinna
Journal:  Ann Transplant       Date:  2018-01-12       Impact factor: 1.530

4.  Graft Pre-conditioning by Peri-Operative Perfusion of Kidney Allografts With Rabbit Anti-human T-lymphocyte Globulin Results in Improved Kidney Graft Function in the Early Post-transplantation Period-a Prospective, Randomized Placebo-Controlled Trial.

Authors:  Paul V Ritschl; Julia Günther; Lena Hofhansel; Anja A Kühl; Arne Sattler; Stefanie Ernst; Frank Friedersdorff; Susanne Ebner; Sascha Weiss; Claudia Bösmüller; Annemarie Weissenbacher; Rupert Oberhuber; Benno Cardini; Robert Öllinger; Stefan Schneeberger; Matthias Biebl; Christian Denecke; Christian Margreiter; Thomas Resch; Felix Aigner; Manuel Maglione; Johann Pratschke; Katja Kotsch
Journal:  Front Immunol       Date:  2018-08-24       Impact factor: 7.561

Review 5.  Potential Applications of Extracellular Vesicles in Solid Organ Transplantation.

Authors:  Cristina Grange; Linda Bellucci; Benedetta Bussolati; Andrea Ranghino
Journal:  Cells       Date:  2020-02-05       Impact factor: 6.600

Review 6.  Shifting Paradigms for Suppressing Fibrosis in Kidney Transplants: Supplementing Perfusion Solutions With Anti-fibrotic Drugs.

Authors:  L Leonie van Leeuwen; Henri G D Leuvenink; Peter Olinga; Mitchel J R Ruigrok
Journal:  Front Med (Lausanne)       Date:  2022-01-10

7.  Prediction of renal function upon reperfusion by ex situ controlled oxygenated rewarming.

Authors:  Thomas Minor; Katja Sutschet; Oliver Witzke; Andreas Paul; Anja Gallinat
Journal:  Eur J Clin Invest       Date:  2016-10-26       Impact factor: 4.686

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.